Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Journal of clinical pharmacology 20121001

Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

Diabetes, obesity & metabolism 20121001

Recent advances in incretin-based therapies.

Clinical endocrinology 20121001

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.

Bioorganic & medicinal chemistry 20121001

Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.

Current medical research and opinion 20121001

Linagliptin as add-on therapy for type 2 diabetes - an overview.

Drugs of today (Barcelona, Spain : 1998) 20121001

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Current clinical pharmacology 20120801

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Clinical pharmacokinetics 20120801

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Bioanalysis 20120801

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.

Primary care diabetes 20120701

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Drug metabolism and disposition: the biological fate of chemicals 20120701

The incretin hormones: from scientific discovery to practical therapeutics.

Diabetologia 20120701

Pharmacokinetic study of saxagliptin in healthy Chinese subjects.

Clinical drug investigation 20120701

Drug-induced hypoglycaemia in type 2 diabetes.

Expert opinion on drug safety 20120701

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Diabetes, obesity & metabolism 20120601

An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Current diabetes reviews 20120501

Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.

Diabetes, obesity & metabolism 20120401

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Diabetes & metabolism 20120401

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

Current medical research and opinion 20120401

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Diabetes technology & therapeutics 20120401

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Diabetes, obesity & metabolism 20120401

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

Diabetes/metabolism research and reviews 20120301

Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.

Annals of medicine 20120301

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Clinical drug investigation 20120301

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

Expert opinion on drug metabolism & toxicology 20120301

Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

The Annals of pharmacotherapy 20120301

Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.

Minerva endocrinologica 20120301

Pleiotropic effects of incretins.

Indian journal of endocrinology and metabolism 20120301

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

Drugs 20120122

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.

Diabetes technology & therapeutics 20120101

A review of gliptins in 2011.

Expert opinion on pharmacotherapy 20120101

Metformin + saxagliptin for type 2 diabetes.

Expert opinion on pharmacotherapy 20120101

DPP-4 inhibitors and lipids: systematic review and meta-analysis.

Advances in therapy 20120101

A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.

Journal of clinical pharmacology 20120101

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Cardiovascular diabetology 20120101

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Cardiovascular diabetology 20120101

A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.

Pharmacoepidemiology and drug safety 20120101

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.

Diabetology & metabolic syndrome 20120101

The influence of incretin mimetics on cardiovascular risk factors in diabetes.

ISRN endocrinology 20120101

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

BMC pharmacology 20120101

Uncovering undetected hypoglycemic events.

Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Experimental diabetes research 20120101

Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

ISRN endocrinology 20120101

Red carpeting the newer antidiabetics.

Journal of pharmacology & pharmacotherapeutics 20120101

The management of type 2 diabetic patients with hypoglycaemic agents.

ISRN endocrinology 20120101

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.

Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

Revista da Associacao Medica Brasileira (1992) 20120101

Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.

Swiss medical weekly 20120101

Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.

The Journal of organic chemistry 20111216

Impact of diabetes on postinfarction heart failure and left ventricular remodeling.

Current heart failure reports 20111201

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

International journal of clinical practice 20111201

[Incretin-based therapy for treating patients with type 2 diabetes].

Orvosi hetilap 20111127

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

Diabetes, obesity & metabolism 20111101

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.

Diabetes research and clinical practice 20111101

Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Clinical therapeutics 20111101

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

American heart journal 20111101

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

Current medical research and opinion 20111101

[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

Orvosi hetilap 20110911

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20110901

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.

Annales d'endocrinologie 20110901

Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.

Recent patents on endocrine, metabolic & immune drug discovery 20110901

Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

Journal of medicinal chemistry 20110825

Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.

The American journal of cardiology 20110802

Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.

Clinical therapeutics 20110801

Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.

Southern medical journal 20110801

Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.

Expert opinion on drug discovery 20110801

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Drugs 20110730

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Diabetes, obesity & metabolism 20110701

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.

Diabetes, obesity & metabolism 20110701

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.

British journal of clinical pharmacology 20110701

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.

Postgraduate medicine 20110701

Health economic evaluation of dipeptidyl peptidase-4 inhibitors.

Indian journal of endocrinology and metabolism 20110701

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.

Diabetes, obesity & metabolism 20110601

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

Diabetes, obesity & metabolism 20110601

The many faces of the adamantyl group in drug design.

European journal of medicinal chemistry 20110601

Place in therapy for liraglutide and saxagliptin for type 2 diabetes.

Southern medical journal 20110601

Recent diabetes issues affecting the primary care clinician.

Southern medical journal 20110601

Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (α-N-protected)-L-ornithine using a transaminase or an amine oxidase.

Enzyme and microbial technology 20110506

An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

Contemporary clinical trials 20110501

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

Diabetes care 20110501

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Clinical therapeutics 20110501

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

Clinical therapeutics 20110501

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.

Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501

Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.

Journal of medicinal chemistry 20110414

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

Diabetes, obesity & metabolism 20110401

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.

Current medical research and opinion 20110401

Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.

Analytical and bioanalytical chemistry 20110401

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.

Clinical pharmacokinetics 20110401

FDA's first active medical product surveillance eyes antidiabetic-MI link.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.

Diabetes & vascular disease research 20110401

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.

Diabetes & vascular disease research 20110401

[Incretin therapy and the metabolic syndrome].

Vnitrni lekarstvi 20110401

Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.

The Medical letter on drugs and therapeutics 20110321

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

Diabetes, obesity & metabolism 20110301

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.

Diabetes therapy : research, treatment and education of diabetes and related disorders 20110301

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.

Diabetes care 20110201

Alogliptin for the treatment of type 2 diabetes.

Drugs of today (Barcelona, Spain : 1998) 20110201

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Hospital practice (1995) 20110201

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

Prescrire international 20110201

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

Journal of medicinal chemistry 20110127

Weight considerations in pharmacotherapy for type 2 diabetes.

Journal of obesity 20110101

Understanding diabetes in patients with HIV/AIDS.

Diabetology & metabolic syndrome 20110101

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Postgraduate medicine 20110101

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.

Journal of medical case reports 20110101

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

BMC endocrine disorders 20110101

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

Journal of atherosclerosis and thrombosis 20110101

Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.

PloS one 20110101

Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.

Indian journal of endocrinology and metabolism 20110101

From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

Experimental diabetes research 20110101

Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.

Journal of nutrition and metabolism 20110101

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

Clinical drug investigation 20110101

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Cardiovascular diabetology 20110101

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

The open medicinal chemistry journal 20110101

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

Journal of pharmacology & pharmacotherapeutics 20110101

South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

Indian journal of endocrinology and metabolism 20110101

Choosing a gliptin.

Indian journal of endocrinology and metabolism 20110101

Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

Open medicine : a peer-reviewed, independent, open-access journal 20110101

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

PloS one 20110101

Management of diabetes across the course of disease: minimizing obesity-associated complications.

Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.

Clinical pharmacology : advances and applications 20110101

[Treatment of diabetes mellitus in dialysis patients].

Terapevticheskii arkhiv 20110101

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.

Clinical medicine insights. Endocrinology and diabetes 20110101

Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.

Mayo Clinic proceedings 20101201

1-Adamantylmethyl 2-amino-benzoate.

Acta crystallographica. Section E, Structure reports online 20101201

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

DPP-4 inhibitors: what may be the clinical differentiators?

Diabetes research and clinical practice 20101101

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

International journal of clinical practice 20101101

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.

Journal of clinical pharmacology 20101001

SLCO1B1 polymorphism and oral antidiabetic drugs.

Basic & clinical pharmacology & toxicology 20101001

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Expert opinion on drug metabolism & toxicology 20101001

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.

Current medical research and opinion 20101001

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

Diabetes/metabolism research and reviews 20101001

Liraglutide: effects beyond glycaemic control in diabetes treatment.

International journal of clinical practice. Supplement 20101001

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

The American journal of geriatric pharmacotherapy 20101001

Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100915

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Clinical pharmacokinetics 20100901

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.